Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions
ATTR Amyloidosis Wild Type
Interventions
DRUG

Dobutrex

Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.

Trial Locations (1)

8200

RECRUITING

Department of Cardiology, Aarhus University Hospital, Aarhus

All Listed Sponsors
lead

Steen Hvitfeldt Poulsen

OTHER